{"transactions":[{"id":3391075,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":154364,"kind":"organization","name":"Q-Ventures Program II (Co-Invest Holdings) Ltd.","position":1,"cik":"0001790363","reported_name":"Q-Ventures Program II (Co-Invest Holdings) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Holder"}},{"id":154365,"kind":"person","name":"Angella Frank G.","position":2,"cik":"0001791076","reported_name":"Angella Frank G.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Holder"}},{"id":154366,"kind":"person","name":"Quinn Christopher","position":3,"cik":"0001791072","reported_name":"Quinn Christopher","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Holder"}}],"security":"Series B Convertible Preferred Stock","published_at":"2019-10-18T20:21:39.000Z","date":"2019-10-16","kind":"exercise","acquired":false,"shares":555555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Convertible Preferred Stock (\"Series B\") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the IPO. The Series B had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Convertible Preferred Stock (\"Series B\") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the IPO. The Series B had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Convertible Preferred Stock (\"Series B\") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the IPO. The Series B had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are beneficially owned by Q-Ventures Program II (Co-Invest Holdings) Ltd. (\"Q-Ventures\"). Frank Angella and Christopher Quinn are the directors of Q-Ventures and have shared voting and investment power over the shares held by Q-Ventures and, as a result, may each be deemed to beneficially own the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":555555},"source":{"system":"sec-edgar","filing":"0000899243-19-025772","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000089924319025772/doc4.xml","form_type":"4"}},{"id":3391074,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":154364,"kind":"organization","name":"Q-Ventures Program II (Co-Invest Holdings) Ltd.","position":1,"cik":"0001790363","reported_name":"Q-Ventures Program II (Co-Invest Holdings) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Holder"}},{"id":154365,"kind":"person","name":"Angella Frank G.","position":2,"cik":"0001791076","reported_name":"Angella Frank G.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Holder"}},{"id":154366,"kind":"person","name":"Quinn Christopher","position":3,"cik":"0001791072","reported_name":"Quinn Christopher","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Holder"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2019-10-18T20:21:39.000Z","date":"2019-10-16","kind":"exercise","acquired":false,"shares":1111111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A-1 Convertible Preferred Stock (\"Series A\") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the Issuer's public offering of Common Stock pursuant to the Issuer's registration statement under the Securities Act of 1933, as amended, filed with the Securities and Exchange Commission on September 3, 2019, as amended on September 30, 2019 (the \"IPO\"). The Series A had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A-1 Convertible Preferred Stock (\"Series A\") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the Issuer's public offering of Common Stock pursuant to the Issuer's registration statement under the Securities Act of 1933, as amended, filed with the Securities and Exchange Commission on September 3, 2019, as amended on September 30, 2019 (the \"IPO\"). The Series A had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A-1 Convertible Preferred Stock (\"Series A\") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the Issuer's public offering of Common Stock pursuant to the Issuer's registration statement under the Securities Act of 1933, as amended, filed with the Securities and Exchange Commission on September 3, 2019, as amended on September 30, 2019 (the \"IPO\"). The Series A had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are beneficially owned by Q-Ventures Program II (Co-Invest Holdings) Ltd. (\"Q-Ventures\"). Frank Angella and Christopher Quinn are the directors of Q-Ventures and have shared voting and investment power over the shares held by Q-Ventures and, as a result, may each be deemed to beneficially own the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1111111},"source":{"system":"sec-edgar","filing":"0000899243-19-025772","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000089924319025772/doc4.xml","form_type":"4"}},{"id":3391073,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":154364,"kind":"organization","name":"Q-Ventures Program II (Co-Invest Holdings) Ltd.","position":1,"cik":"0001790363","reported_name":"Q-Ventures Program II (Co-Invest Holdings) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Holder"}},{"id":154365,"kind":"person","name":"Angella Frank G.","position":2,"cik":"0001791076","reported_name":"Angella Frank G.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Holder"}},{"id":154366,"kind":"person","name":"Quinn Christopher","position":3,"cik":"0001791072","reported_name":"Quinn Christopher","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Holder"}}],"security":"Common Stock","published_at":"2019-10-18T20:21:39.000Z","date":"2019-10-16","kind":"exercise","acquired":true,"shares":555555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Convertible Preferred Stock (\"Series B\") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the IPO. The Series B had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are beneficially owned by Q-Ventures Program II (Co-Invest Holdings) Ltd. (\"Q-Ventures\"). Frank Angella and Christopher Quinn are the directors of Q-Ventures and have shared voting and investment power over the shares held by Q-Ventures and, as a result, may each be deemed to beneficially own the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest therein."}],"balance_after":1666666,"source":{"system":"sec-edgar","filing":"0000899243-19-025772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000089924319025772/doc4.xml","form_type":"4"}},{"id":3391072,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":154364,"kind":"organization","name":"Q-Ventures Program II (Co-Invest Holdings) Ltd.","position":1,"cik":"0001790363","reported_name":"Q-Ventures Program II (Co-Invest Holdings) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Holder"}},{"id":154365,"kind":"person","name":"Angella Frank G.","position":2,"cik":"0001791076","reported_name":"Angella Frank G.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Holder"}},{"id":154366,"kind":"person","name":"Quinn Christopher","position":3,"cik":"0001791072","reported_name":"Quinn Christopher","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Holder"}}],"security":"Common Stock","published_at":"2019-10-18T20:21:39.000Z","date":"2019-10-16","kind":"exercise","acquired":true,"shares":1111111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A-1 Convertible Preferred Stock (\"Series A\") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the Issuer's public offering of Common Stock pursuant to the Issuer's registration statement under the Securities Act of 1933, as amended, filed with the Securities and Exchange Commission on September 3, 2019, as amended on September 30, 2019 (the \"IPO\"). The Series A had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are beneficially owned by Q-Ventures Program II (Co-Invest Holdings) Ltd. (\"Q-Ventures\"). Frank Angella and Christopher Quinn are the directors of Q-Ventures and have shared voting and investment power over the shares held by Q-Ventures and, as a result, may each be deemed to beneficially own the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest therein."}],"balance_after":1111111,"source":{"system":"sec-edgar","filing":"0000899243-19-025772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000089924319025772/doc4.xml","form_type":"4"}}]}